Loading
A phase 3 trial of Ivonescimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, now recruiting.
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 is a phase 3 interventional study registered as NCT06767514 by Summit Therapeutics, with 780 participants planned, started 2025-02-27 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab Injection, Pembrolizumab Injection. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Summit Therapeutics, Ivonescimab, PD-L1-high non-small-cell lung cancer without a driver mutation, Bispecific antibodies.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Pembrolizumab.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Summit Therapeutics, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/